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Background: Hemorrhoids are a common disorder that affects the quality of life of millions of people worldwide.
The effectiveness of OTC medication is limited and they mainly provide symptomatic relief. In order to treat this
ailment, we formulated PP110 Gel and Wipes, as a novel treatment for hemorrhoids. PP110 is based on known
active ingredients with a topical film-forming agent designed to provide physical protection and prolonged tissue
contact with the active ingredients.
Methods: PP110 Gel, PP110 Wipes and the comparator Preparation-H® were used on three patient cohorts. Treatment
was administered once daily for PP110, and three-four times daily for Preparation-H®, for 14 days. Six different clinical
parameters relating to common symptoms of hemorrhoids were monitored.
Results: PP110 Gel was significantly better than Preparation-H® in reducing bleeding (Δ = 6 %), providing pain relief
(Δ = 10 %) and controlling itching (Δ = 11 %). These three parameters are considered as the most common distressing
symptoms for hemorrhoids patients, demonstrating that PP110 is superior to conventional treatment.
Conclusion: This study demonstrated the efficacy of the PP110 Gel in treating hemorrhoids and its superiority to
conventional treatments. The PP110 film-based formulation provides a slow-release mechanism and as a consequence,
a prolonged therapeutic window. PP110 was both more effective in reducing hemorrhoids symptoms and more
convenient to use, in that it only required application once per day.
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The prevalence of hemorrhoids is extremely high in
Western and other industrialized societies, with millions
affected worldwide [1, 2]. In the United States it is esti-
mated that over 10 million people suffer from hemor-
rhoids related symptoms [1], However, the real number of
people suffering from hemorrhoids is considered much
higher than that due to poor patient reporting [3, 4].
The anorectal disorder of hemorrhoids is caused by in-
creased pressure on rectal and pelvic tissue veins, most* Correspondence: prof.ehud.klein@gmail.com
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disease when symptomatic. Common symptoms include
pain, itching, swelling, anal discomfort and rectal bleed-
ing [5], all of which severely affect patient quality of life
[4]. Bleeding during bowel movements, itching, and rec-
tal pain are considered as the most common hemorrhoid
symptoms [3, 6]. Hemorrhoids are most prevalent in the
45–65 year-old age group, with the same prevalence be-
tween genders. One of the ways to prevent hemorrhoids
is by maintaining a healthy lifestyle based on a fiber-
enriched diet with overhydrating, but this does not al-
ways help [7, 8].cle distributed under the terms of the Creative Commons Attribution License
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counter (OTC) preparations [2], products that typically
contain active analgesics, vasoconstrictors, corticosteroids,
or lubricants and provide temporary symptomatic relief.
These products come in various forms including oint-
ments, creams, gels, suppositories, and medicated wipes
[9, 10]. Preparation-H® hemorrhoidal Cream (Pfizer) is
arguably one of the world's best-selling hemorrhoids treat-
ments [11].
One of the major challenges with current treatments is
the demanding treatment regimen, which requires appli-
cation several times a day. To overcome this problem
and to improve patient compliance we devised PP110
Gel and PP110 Wipes, two novel formulations that were
designed with a film-forming agent, for the treatment of
grade 2–3 hemorrhoids (Grade 2: hemorrhoids which
prolapse upon bearing down, but spontaneous reduction;
Grade 3: hemorrhoids which prolapse upon bearing down
requiring manual reduction). The film forms a protective
layer, providing ‘band-aid like’ physical protection and
prolonged skin contact with the active ingredients. The
aim of this study is to assess the efficacy and safety of the
product and to compare them to those of Preparation-H®
cream in a prospective, randomized study.
Methods
Study design
This study was a multicenter (n = 7), randomized, open,
3-arm parallel group trial carried out in community
clinics in Israel. Before enrolment, all participants re-
ceived orally delivered and written information about
the study and voluntarily signed a consent form. The
trial was conducted in accordance to the ethical princi-
ples of the Declaration of Helsinki and approved by the
Maccabi Healthcare Ethics Committee (Tel-Aviv, Israel;
study number 2013058).
Patients were randomly assigned to the PP110 Gel,
PP110 Wipes, or Preparation-H® Maximum Strength
Cream treatment cohorts. It should be noted that while
Preparation-H® is a common OTC product in the USA
and other countries, it is unavailable for sale in Israel,
thus local patients have no prior knowledge or expect-
ation from Preparation-H®.
Patients
Patients aged 18–70 with mildly bleeding grade 2 or 3
hemorrhoids were eligible to participate in the study.
Patients with known rectal sensitivity, rectal infection,
use of anti-coagulants (except Aspirin or Plavix), known
inflammatory bowel disease, anal fissures, current diag-
nosis of cancer, and/or pregnancy were excluded from
the study.
Patients in the two test arms were instructed to apply
PP110 once daily for 14 days, 1–5 min prior to the firstbowel movement, in order to allow the film to form and
serve as a protective layer. Patients in the comparator
arm were instructed to use Preparation-H® per label, i.e.,
3–4 times per day, after bowel movement. Patients were
contacted by phone or by means of a text message every
2–3 days, to maximize compliance and adherence.
Bleeding (the primary endpoint), pain, itching, swell-
ing, discharge and discomfort were recorded by the
recruiting physician at baseline. Pain was measured on a
Visual Analogue Scale (VAS) from 0 (“No Pain”) to 10
(“Maximal Pain”), while the remaining parameters were
measured on a 4-point Likert scale consisting of: 1
(“None”), 2 (“Minimal”), 3 (“Moderate”) and 4 (“Signifi-
cant”). At the end of each day during the 14-day treat-
ment period, patients completed a short questionnaire
regarding their clinical symptoms. After 14 days of treat-
ment, patients visited the clinic for a follow up visit,
where the physician performed a final evaluation of the
six parameters. During the same visit, patients were
asked to complete a feedback questionnaire addressing
treatment efficacy and overall satisfaction. A week later,
they were contacted again by phone to verify their over-
all well-being. Safety parameters were recorded through-
out the treatment and follow up periods.
Withdrawals
Nine patients withdrew early and their data were lost.
Some of them did not provide a reason (5 cases), others
claimed they had lost their diary (2 cases), one claimed
he did not in fact have hemorrhoids and one (from the
PP110 Gel group) decided to stop using treatment since
his bleeding worsened. Distribution of patients among
arms (3 for PP110 Gel, 1 for PP110 Wipes and 5 for
Preparation-H®) does not show significant differences. In
addition, four patients were removed from the efficacy
analysis due to major protocol violations.
Materials
PP110 (Peritech Pharma LTD, Israel) is a gel or liquid
based product, comprising an oil-in-water emulsion. Ac-
tive ingredients (Pramoxine HCl 0.25 % and Phenyleph-
rine HCl 1 %) are dissolved in the aqueous phase. To
manufacture the Gel formulation we added a gelling
agent, which is stable at high ionic strength. The oily
phase mainly contains volatile ingredients with a film-
forming polymer. Upon application, the volatile materials
evaporate leaving the polymer attached to the tissue, along
with the active ingredients. The Liquid formulation is ap-
plied to folded fabric wipes, which are then individually
sealed in laminated sachettes.
Preparation-H® Maximum strength is commercially
available in the USA in cream form and contains the
same active ingredients at the same concentrations (Pra-
moxine HCl 0.25 % and Phenylephrine HCl 1 %) [12].
Table 1 Patient baseline demographics and characteristics
PP110 Gel PP110 Wipes Preparation-H® All arms P-Value*
(N = 34) (N = 33) (N = 34) (N = 101)
Gender, n (%)
Female 17 (50 %) 22 (67 %) 21 (62 %) 60 (59 %) 0.36
Male 17 (50 %) 11 (33 %) 13 (38 %) 41 (41 %)
Age (Mean ± SD) 54.9 ± 11.1 53.3 ± 14.2 55.3 ± 14.6 54.5 ± 13.2 0.81
Hemorrhoid grade, n (%)
2 17 (50 %) 14 (42 %) 23 (68 %) 54 (53 %) 0.10
3 17 (50 %) 19 (58 %) 11 (32 %) 47 (47 %)
History of hemorrhoids, n (%)
Less than 1 year 6 (18 %) 1 (3 %) 11 (32 %) 18 (18 %) 0.01
1 to 2 years 4 (12 %) 1 (3 %) 4 (12 %) 9 (9 %)
2 to 5 years 4 (12 %) 12 (36 %) 5 (15 %) 21 (21 %)
5 to 10 years 3 (9 %) 5 (15 %) 6 (18 %) 14 (14 %)
Over 10 years 17 (50 %) 14 (42 %) 8 (24 %) 39 (39 %)
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Statistical analysis was performed using Analysis Of
Variance (ANOVA), for each of the test arms versus the
control arm (Preparation-H® treatment). Two-sided 95 %
confidence intervals, as well as P-values were used, as
estimated by the ANOVA model. All collected data was
either plotted as the change from baseline (PCB) relative
to the day of treatment, or calculated as the Area under
the curve (AUC) for each graph.
Responders were defined as those who showed an
improvement in any clinical measure between enroll-
ment and last visit, the two recordings performed by the
recruiting physicians only.
Results
No significant inter-arm differences in baseline demographics
and characteristics were observed, except for history ofFig. 1 Flowchart of study inclusion, randomization, and patient dispositionhemorrhoids where both test arms had a longer history
than the control arm (Table 1).
A total of 101 patients were randomly assigned to one
of the three treatment cohorts. Figure 1 summarizes
patient enrolment, randomization, and disposition.
When assessing the impact of the treatments on individ-
ual clinical symptoms, each treatment demonstrated a
marked effect on one or more clinical parameter, which
was either equal to or superior to the other tested treat-
ments. Bleeding, which was the primary endpoint of this
trial improved by more than 30 % within 1–2 days of
treatment in all three arms (Fig. 2a), but was most notably
affected by the PP110 Gel, which yielded a mean 45 %
AUC across the treatment period. The PP110 Wipes and
Preparation-H® yielded a mean 42 % and 39 % bleeding
reduction AUC, respectively. These results resulted with a
p-value of 0.005 for the difference between PP110 Gel and
Fig. 2 Percent Change from Baseline (PCB) in each of the six clinical parameters monitored: Bleeding (a), Pain (b), Itching (c), Swelling (d),
Discharge (e) and Discomfort (f). Baseline is always defined as 0 for each arm. Days 1–14 are self-reported, End visit is evaluated by the physician,
and Follow Up (FU) data is collected over the phone. PP110 Gel is always shown in red, PP110 Wipes in black and Preparation-H® in blue
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the difference between PP110 Wipes and Preparation-H®.
PP110 Gel also provided the greatest pain relief, when
compared to the other treatments, with a mean 21 % im-
provement, while Preparation-H® treatment led to a mean
9 % improvement and PP110 Wipes to a 6 % improve-
ment in pain scores relative to baseline (Fig. 2b).
When applied in wipe form, PP110 treatment provided
significant swelling relief, with a 24.3 % improvement rela-
tive to PP110 Gel (9.2 % improvement) and Preparation-H®
(11 % improvement, Fig. 2d). For itching, no relief wasshown following treatment with either PP110 Wipes or
Preparation-H®, both resulting in symptom exacerbation
of about 12 %; PP110 Gel on the other hand yielded an
improvement of 1 % (Fig. 2c). None of the products
effectively addressed discharge, with PP110 Gel and
Preparation-H® showing a deterioration of 2 %, while
treatment with PP110 Wipes resulted in 9 % deterioration
(Fig. 2e). Finally, discomfort levels improved by 10 %
following Preparation-H® treatment, while PP110 Gel
treatments improved by only 2 % and PP110 Wipes was
associated with exacerbation of the symptom by 3 %
Table 2 Statistical differences in AUC between each of the test arms and the active control arm. PP110 Gel is more effective than
Preparation-H® with respect to bleeding, pain and itching (in a manner that is statistically significant). PP110 Wipes are more effective
than Preparation-H® with respect to swelling, but less effective with respect to pain and discomfort
Symptom PP110 Gel vs. Preparation-H® PP110 Wipes vs. Preparation-H®
Difference Lower CI Upper CI P-value Difference Lower CI Upper CI P-value
Bleeding −0.06 −0.10 −0.02 0.0059 −0.03 −0.08 0.02 0.2034
Pain −0.12 −0.19 −0.04 0.0025 0.15 0.05 0.25 0.0023
Itching −0.13 −0.21 −0.05 0.0008 −0.01 −0.10 0.07 0.7673
Swelling −0.00 −0.05 0.05 0.9367 −0.15 −0.20 −0.10 <.0001
Discharge −0.01 −0.06 0.04 0.6908 0.05 −0.02 0.12 0.1344
Discomfort 0.06 −0.01 0.14 0.0958 0.10 0.03 0.18 0.0084
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ior to Preparation-H® in relieving bleeding, pain and
itching, while PP110 Wipes were significantly superior to
Preparation-H® in addressing swelling (Table 2). However,
PP110 Wipes were significantly inferior to Preparation-H®
in treatment of pain and discomfort.
When using responder analysis the results were
quantitatively different but qualitatively similar. The
PP110 Wipes cohort had 89.7 % bleeding responders,
compared to 76.7 % in the PP110 Gel and 72.4 % in
the Preparation-H® cohorts (p = 0.09). In pain, PP110
Gel treatment led to a 70 % response rate, compared
to 44.8 % in both PP110-Wipes and Preparation-H®
cohorts (p = 0.06). Similarly, itching responders were
30 % in PP110 Gel, and 17.2 % in both PP110 Wipes
and Preparation-H®.
Satisfaction Measures: Patient comfort levels were
slightly higher in the Preparation-H® cohort when com-
pared to the PP110 Gel and Wipe cohorts (Table 3).
Overall satisfaction and likelihood of future use of both
PP110 Wipes and PP110 Gel were higher than
Preparation-H®. Specifically, the first quartile for
Preparation-H® was 2.5, whereas for PP110 Wipes it wasTable 3 Patient comfort, satisfaction and prospects of future
use
Parameter Group Min. 1st Quartile Median 3rd Quartile Max. N
Comfort Gel 1 4.0 5.0 5.0 5 30
Prep-H 2 5.0 5.0 5.0 5 28
Wipes 1 3.0 5.0 5.0 5 29
Satisfaction Gel 1 4.0 4.0 5.0 5 30
Prep-H 1 2.5 4.0 5.0 5 28
Wipes 1 3.0 5.0 5.0 5 29
Future use Gel 1 4.0 5.0 5.0 5 30
Prep-H 1 2.0 4.0 5.0 5 28
Wipes 1 4.0 5.0 5.0 5 293 and for PP110 Gel it was 4. In both test groups, 75 %
of the subjects scored likelihood of future use ≥4,
whereas in the control group, 50 % of subjects provided
scores below 4, half of which were below 2.
Safety: Patient monitoring included recording of treat-
ment related adverse effects (AEs). These included Rash,
burning, discharge and a non-treatment related symp-
tom: Diarrhea (Table 4). No significant treatment related
adverse effects were reported. No other safety related is-
sues were reported.
Discussion
Topical OTC hemorrhoid treatments have been widely
used for several decades. Most of these treatments are
aimed at providing symptomatic relief rather than truly
altering the underlying pathophysiology of the disease.
Even though these treatments are commonly used, data
regarding their efficacy is sparse [13].
Preparation-H® (Pfizer) is arguably the most popular
OTC antihemorrhoidal preparation in the US, and is
available in many forms, including ointment, cream, gel,
suppositories, and medicated wipes. It is said to provide







No. % No. % No. %
Adverse Events - Treatment Related
Itching 4 11.7 % 2 6.1 % 5 14.7 %
Rash 1 2.9 %
Burning 1 3.0 %
Discharge 1 3.0 %
Non-Treatment Related
Diarrhea 1 2.9 %
Total 5 14.7 % 4 12.1 % 6 17.6 %
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clinical trials in this field are scarce and no randomized
controlled trials supporting its acclaimed efficacy have
been documented [3]. To the best of our knowledge,
this is the first publication testing the efficacy of
Preparation-H® in a controlled clinical trial, or in fact in
any trial.
This clinical trial evaluated the effect of PP110 Gel
and medicated Wipes, designed to form a thin protect-
ive layer at the treatment site. This protective layer acts
as both a physical barrier preventing irritation to the
inflamed tissue and as a slow release reservoir of the
active ingredients, with improved tissue contact. This
supports a once-daily application regimen, which is pre-
ferred over up to 4 daily applications required for
Preparation-H®.
The PP110 Gel formulation induced a statistically sig-
nificant improvement, in comparison to Preparation-H®,
in bleeding, pain and itching, the most common dis-
turbing symptoms of hemorrhoids. The PP110 Wipe
formulation was superior to Preparation-H® in treating
swelling, although Preparation-H® was superior to PP110
Wipes in alleviating pain and discomfort. Discomfort
is loosely defined and may have been interpreted dif-
ferently by different patients. A clearer definition of
discomfort symptoms may be advantageous in future
studies.
Despite almost identical formulations, the PP110 Gel
and Wipes formulations, led to significantly different
clinical outcomes, which arose from the advantage pro-
vided by the protective film layer formed following ap-
plication of the product. When using the Wipe
formulation, the concentration of active ingredients
reaching the affected area may be too low to achieve any
beneficial effects. As Wipes were clearly superior over
other arms with respect to swelling, this could be an in-
teresting subject for future studies.
The lack of clinical data regarding the efficacy of
OTC hemorrhoid medications has led many physi-
cians to doubt whether they provide any significant
benefit for patients [13, 14]. The current study is able
to confirm their clinical effects and uncovers signifi-
cant differences between treatment options for the
first time.
Conclusion
This study demonstrated the efficacy of the PP110 Gel
in treating hemorrhoids. The advanced therapeutic film-
based technology provides for a slow-release depot,
which allows for an extended and effective therapeutic
effect, together with dermal protection, and bears signifi-
cant advantages over current treatments. Overall, these
features may advance PP110 Gel to the forefront of
next-generation anti hemorrhoidal therapies.Competing interests
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